The role of CCN1 in kidney-brain crosstalk

Abstract

Cognitive impairment and dementia are major global health problems of the aging human population. It is estimated that about 55 million people were living with dementia in 2019 and this number is expected to triple by 2050. Dementia can result from abnormal structure and function of brain blood vessels that may develop in a variety of conditions including chronic kidney disease (CKD). Recent studies from our laboratory suggest that in addition to controlling blood volume and blood pressure (renin), and blood cell count (erythropoietin), the kidney produces novel systemic angiogenic hormones to maintain blood vessels, such as the matricellular protein Cellular Communication Network factor 1 (CCN1). These hormones are then released to the blood and may act as new molecular mechanisms of kidney-brain crosstalk. We hypothesized that kidney-derived CCN1 helps to preserve the normal structure and function of blood vessels throughout the body, including a healthy blood-brain barrier (BBB). We further hypothesized that reduced plasma CCN1 caused by diminished renal production of CCN1 due to kidney disease plays a major role in the development of brain vascular dysfunction, and therefore in the pathogenesis and progression of dementia and cognitive impairment. Intravital multiphoton (MPM) imaging of the intact mouse brain in control or after 5/6 nephrectomy (5/6 Nx), a well-established mouse model of chronic kidney disease (CKD) was used to measure changes in BBB permeability with or without chronic CCN1 treatment. Kidney and BBB structure/function phenotyping was performed using CCN1 ELISA assay, the Medibeacon transdermal GFR measurement system, tissue harvest, and immunohistochemistry. Compared to control, 5/6 Nx mice had reduced plasma CCN1 levels, reduced GFR, but no difference in systolic blood pressure. MPM imaging showed increased fluorescence intensity of mid-size plasma proteins (A680 conjugated Albumin 70 kDa) compared to high molecular weight markers (A488 conjugated Dextran 500 kDa) in brain interstitium in 5/6 Nx compared to control. In addition, the density of cell-to-cell junctions in brain endothelial cells were 20% reduced in CKD compared to control healthy mice. In brain endothelial cells cultured in vitro, CCN1 treatment had protective effects on cell proliferation, motility and angiogenesis as confirmed by scratch and tube formation assays. In summary, this study identified new mechanisms of kidney-brain crosstalk, and helped to improve our mechanistic understanding of cerebrovascular pathology in CKD. DK123564, DK064324, DK135290. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.